据印度代购了解，特罗凯中国上市已经有一段时间了，在临床的研究和实践中，关于副作用，在进入中国时的临床一期、二期、三期试验中都是备注在案的，而且都需要向药监局申报。针对一期、二期临床试验中出现的皮疹、腹泻等轻微副作用都会先统计一个百分比。

According to Daigou India, tarceva has been on the market in China for some time. In clinical research and practice, the side effects of tarceva have been noted in the phase I, Phase II and Phase III trials when they were introduced into China, and they need to be reported to the Food and Drug Administration. A percentage of minor side effects such as rashes and diarrhea in phase I and II clinical trials are counted first.

据印度代购了解，对于严重的不良反应，在中国，药品上市前、上市中、上市后都有相应的收集制度。药品上市之后如果出现严重的不良现象，医院的药剂科都有责任上报当地的药监部门，然后再上报到国家药物不良反应监测中心。

据印度代购了解，目前在中国的临床上还尚且没有出现特罗凯副作用致死的案例。临床上，特罗凯被更多地使用于吸烟男性的鳞癌，给人感觉似乎特罗凯的适用人群更广。

According to daigou India, there is no case of death caused by tarceva side effect in China. Clinically, tarceva is more commonly used for squamous cell carcinoma in men who smoke, giving the impression that tarceva may be applicable to a wider population.